JP6208140B2 - キノリン誘導体の調製プロセス - Google Patents

キノリン誘導体の調製プロセス Download PDF

Info

Publication number
JP6208140B2
JP6208140B2 JP2014537359A JP2014537359A JP6208140B2 JP 6208140 B2 JP6208140 B2 JP 6208140B2 JP 2014537359 A JP2014537359 A JP 2014537359A JP 2014537359 A JP2014537359 A JP 2014537359A JP 6208140 B2 JP6208140 B2 JP 6208140B2
Authority
JP
Japan
Prior art keywords
mixture
compound
acid
formula
polar aprotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014537359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530880A (ja
Inventor
ジョー アン ウィルソン，
ジョー アン ウィルソン，
スリラム ナガナサン，
スリラム ナガナサン，
マシュー プファイファー，
マシュー プファイファー，
ニール ジー． アンデルセン，
ニール ジー． アンデルセン，
Original Assignee
エクセリクシス， インク．
エクセリクシス， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47146705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6208140(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エクセリクシス， インク．, エクセリクシス， インク． filed Critical エクセリクシス， インク．
Publication of JP2014530880A publication Critical patent/JP2014530880A/ja
Application granted granted Critical
Publication of JP6208140B2 publication Critical patent/JP6208140B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2014537359A 2011-10-20 2012-10-22 キノリン誘導体の調製プロセス Active JP6208140B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549312P 2011-10-20 2011-10-20
US61/549,312 2011-10-20
PCT/US2012/061320 WO2013059788A1 (en) 2011-10-20 2012-10-22 Process for preparing quinoline derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017112355A Division JP2017222648A (ja) 2011-10-20 2017-06-07 キノリン誘導体の調製プロセス

Publications (2)

Publication Number Publication Date
JP2014530880A JP2014530880A (ja) 2014-11-20
JP6208140B2 true JP6208140B2 (ja) 2017-10-04

Family

ID=47146705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014537359A Active JP6208140B2 (ja) 2011-10-20 2012-10-22 キノリン誘導体の調製プロセス
JP2017112355A Pending JP2017222648A (ja) 2011-10-20 2017-06-07 キノリン誘導体の調製プロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017112355A Pending JP2017222648A (ja) 2011-10-20 2017-06-07 キノリン誘導体の調製プロセス

Country Status (23)

Country Link
US (3) US9365516B2 (enExample)
EP (1) EP2768796B1 (enExample)
JP (2) JP6208140B2 (enExample)
KR (1) KR102075371B1 (enExample)
CN (2) CN104395284A (enExample)
AR (1) AR088483A1 (enExample)
AU (2) AU2012325768B2 (enExample)
BR (1) BR112014009302B1 (enExample)
CA (1) CA2852771C (enExample)
DK (1) DK2768796T3 (enExample)
EA (1) EA031485B1 (enExample)
ES (1) ES2765013T3 (enExample)
GE (1) GEP20207110B (enExample)
HU (1) HUE048023T2 (enExample)
IL (1) IL232139A (enExample)
IN (1) IN2014CN02971A (enExample)
MX (1) MX343288B (enExample)
PL (1) PL2768796T3 (enExample)
PT (1) PT2768796T (enExample)
TW (2) TWI619694B (enExample)
UA (1) UA116876C2 (enExample)
WO (1) WO2013059788A1 (enExample)
ZA (1) ZA201402579B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009722A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
TW201309650A (zh) 2011-02-10 2013-03-01 艾克塞里克斯公司 製造喹啉化合物之方法及包含該化合物之醫藥組合物
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
EP2704717A1 (en) 2011-05-02 2014-03-12 Exelixis, Inc. Method of treating cancer and bone cancer pain
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
PL2768796T3 (pl) * 2011-10-20 2020-05-18 Exelixis, Inc. Sposób wytwarzania pochodnych chinoliny
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
GEP20196995B (en) 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
CN104649969B (zh) * 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
CN106255499A (zh) 2014-03-17 2016-12-21 埃克塞里艾克西斯公司 卡博替尼制剂的给药
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
EA033834B1 (ru) 2014-07-31 2019-11-29 Exelixis Inc Способ получения кабозантиниба, меченного фтором-18, и его аналогов
MA40457A (fr) 2014-08-05 2017-06-14 Exelixis Inc Combinaison de médicaments pour traiter le myélome multiple
CN108026035B (zh) * 2015-09-02 2021-03-30 陈昆锋 具有蛋白酪氨酸磷酸酶shp-1激动剂活性的化合物
US11141413B2 (en) 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
CN109836382B (zh) * 2017-11-29 2021-11-05 江苏豪森药业集团有限公司 苹果酸卡博替尼及其中间体的制备方法
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
FI4143169T3 (fi) 2020-04-30 2026-06-08 Exelixis Inc Kinaasi-inhibiittorin valmistusmenetelmät
CN112142619B (zh) * 2020-10-20 2023-01-10 浙江工业大学 一种1,1-环丙烷二羧酸酰胺类化合物及其制备方法和应用
CA3202761A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
US20240190825A1 (en) * 2021-03-24 2024-06-13 Biocon Limited Process for preparation of cabozantinib
AU2023384196A1 (en) * 2022-11-25 2025-06-12 Msn Laboratories Private Limited, R&D Center Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation
KR20250136810A (ko) 2023-01-31 2025-09-16 한다 온콜로지, 엘엘씨 개선된 카보잔티닙 조성물 및 사용 방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
CA2572331A1 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
WO2006108059A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
CA2743416A1 (en) 2008-11-13 2010-05-20 Exelixis Inc. Methods of preparing quinoline derivatives
US20130030172A1 (en) 2008-12-04 2013-01-31 Exelixis, Inc. Methods of Preparing Quinoline Derivatives
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
BR112012001118A2 (pt) 2009-07-17 2016-02-23 Exelixis Inc formas cristalinas de n-[3-flúor-4-({6-(metilóxi)-7-[(3-morfolin-4-ilpropil)óxi]-quinolin-4-il}óxi)fenil]-n'-(4-fluorfenil)ciclopropano-1,1-dicarboxamida, composição farmacêutica com as mesmas, métodos de preparação das mesmas e tratamento de câncer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EA201290906A1 (ru) 2010-03-12 2013-03-29 Экселиксис, Инк. Кристаллогидратные формы n-[3-фтор-4-({6-(метилокси)-7-[(3-морфолин-4-илпропил)окси]хинолин-4-ил}окси)фенил]-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EP2593091A1 (en) 2010-07-16 2013-05-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
WO2012009722A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
EP2621482A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
US20130252956A1 (en) 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
TW201309650A (zh) 2011-02-10 2013-03-01 艾克塞里克斯公司 製造喹啉化合物之方法及包含該化合物之醫藥組合物
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
EP2704717A1 (en) 2011-05-02 2014-03-12 Exelixis, Inc. Method of treating cancer and bone cancer pain
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
PL2768796T3 (pl) 2011-10-20 2020-05-18 Exelixis, Inc. Sposób wytwarzania pochodnych chinoliny
MX2014005458A (es) 2011-11-08 2015-04-16 Exelixis Inc Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer.
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
JP6513567B2 (ja) 2012-09-07 2019-05-15 エクセリクシス， インク． 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤

Also Published As

Publication number Publication date
TW201321342A (zh) 2013-06-01
EP2768796A1 (en) 2014-08-27
KR102075371B1 (ko) 2020-02-10
JP2014530880A (ja) 2014-11-20
CN110511158A (zh) 2019-11-29
CN104395284A (zh) 2015-03-04
PT2768796T (pt) 2020-02-21
IL232139A (en) 2017-11-30
AR088483A1 (es) 2014-06-11
NZ624328A (en) 2016-10-28
TWI619694B (zh) 2018-04-01
TWI642650B (zh) 2018-12-01
EP2768796B1 (en) 2019-11-20
CA2852771C (en) 2019-11-26
IN2014CN02971A (enExample) 2015-07-03
AU2012325768A1 (en) 2014-05-22
UA116876C2 (uk) 2018-05-25
GEAP201913471A (en) 2019-10-25
HUE048023T2 (hu) 2020-05-28
BR112014009302A2 (pt) 2017-05-23
NZ723880A (en) 2018-03-23
US20160229805A1 (en) 2016-08-11
US9969692B2 (en) 2018-05-15
ZA201402579B (en) 2015-03-25
BR112014009302B1 (pt) 2020-04-28
EA031485B1 (ru) 2019-01-31
EA201490831A1 (ru) 2014-09-30
TW201731812A (zh) 2017-09-16
IL232139A0 (en) 2014-05-28
MX2014004583A (es) 2014-10-06
US9365516B2 (en) 2016-06-14
WO2013059788A1 (en) 2013-04-25
PL2768796T3 (pl) 2020-05-18
KR20140088874A (ko) 2014-07-11
US20140256938A1 (en) 2014-09-11
MX343288B (es) 2016-11-01
AU2017254982A1 (en) 2017-11-23
CA2852771A1 (en) 2013-04-25
GEP20207110B (en) 2020-05-25
AU2012325768B2 (en) 2017-08-10
DK2768796T3 (da) 2020-02-24
JP2017222648A (ja) 2017-12-21
US20180230100A1 (en) 2018-08-16
HK1201517A1 (en) 2015-09-04
ES2765013T3 (es) 2020-06-05

Similar Documents

Publication Publication Date Title
JP2017222648A (ja) キノリン誘導体の調製プロセス
TWI640509B (zh) 製造喹啉化合物之方法及包含該化合物之醫藥組合物
CN106083714B (zh) N-(4-{[6,7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n′-(4-氟苯基)环丙烷-1,1-二甲酰胺苹果酸盐及其结晶型
KR20120051702A (ko) Ｎ-〔３-플루오로-４-(｛６-(메틸옥시)-７-〔(３-모르폴린-４-일프로필)옥시〕퀴놀린-４-일｝옥시)페닐〕-ｎ''-(４-플루오로페닐)시클로프로판-１,１-디카르복사미드의 결정형
EP2970123B2 (en) Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation
WO2025002355A9 (zh) 一种jak2抑制剂的晶型及制备方法
WO2016101867A1 (zh) 萘普替尼对甲苯磺酸盐的α晶型及制备方法和含有其的药物组合物
NZ723880B2 (en) Process for preparing quinoline derivatives
NZ624328B2 (en) Process for preparing quinoline derivatives
HK1201517B (en) Process for preparing quinoline derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170720

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170906

R150 Certificate of patent or registration of utility model

Ref document number: 6208140

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250